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Increased cardiovascular risk factors and features of endothelial
activation and dysfunction in dialyzed uremic patients. Due to the
incidence of symptomatic atherosclerosis in uremic patients, hemostasis-
derived cardiovascular risk factors, basal plasma concentrations of some
endothelial-derived glycoproteins and desmopressin-induced variations of
endothelial-derived proteins were studied in 22 uremic patients on
prolonged maintenance hemodialysis with no cardiovascular antecedent.
Compared to control subjects, patients had increased predialysis hemo-
stasis-related cardiovascular risk factors: high fibrinogen, proconvertin,
and type 1 plasminogen activator inhibitor plasma concentrations; low
albumin values; generally low antithrombin III values but sometimes high.
They had high predialysis plasma concentrations of endothelium-derived
glycoproteins: von Willebrand factor, tissue-type plasminogen activator
and urokinase-type plasminogen activator, which are secreted by endo-
thelial cells, but also soluble thrombomodulin, a marker of endothelial cell
injury. The desmopressin-induced release of tissue-type plasminogen
activator and of von Willebrand factor were lower than in controls. High
fibrinogen, type 1 plasminogen activator inhibitor and low albumin plasma
concentrations may be linked to repeated acute phase reactions associated
with hemodialysis. Data concerning endothelium-related proteins are
concordant with the co-existence of a chronic in vivo endothelial activation
and endothelial injury in uremia. This could be linked to the initiation and
progression of atherosclerosis.
Bleeding has been recognized as a complication of uremia as
early as 1907 [1]. Maintenance hemodialysis has reduced the
incidence of hemorrhage but is paradoxically associated to accel-
erated atherosclerosis [21 and to increased atherogenesis-related
cardiovascular mortality [3, 4]. Endothelial dysfunction is classi-
cally thought to be central to atherogenesis [5] and an impaired
venous-occlusion induced release of two endothelium-derived
glycoproteins, namely von Willebrand factor (vWF) and tissue-
type plasminogen activator (t-PA) has been described in hemodi-
alysis patients though responses in undialyzed patients were
normal [6]. Endothelial dysfunction characterized by decreased
t-PA related antigen (t-PA Ag) release, raised basal plasma vWF
related antigen (vWF Ag) concentration and transcapillary albu-
min escape [7] has been associated with early diabetic nephropa-
thy. Short lasting infusions of deamino-8-D-arginine vasopressin
(dDAVP; desmopressin) can be used for temporary correction of
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the bleeding time in uremia [8] and induce the release of some of
the substances present in the endothelial cells: vWF, t-PA [re-
viewed 9] and urokinase-type plasminogen activator (u-PA) [10].
Prospective studies have already established a strong relation-
ship between the subsequent incidence of cardiovascular diseases
and the plasma levels of the following so-called cardiovascular risk
factors: fibrinogen (Fg) [11—13], coagulation factor VII (procon-
vertin: FVII) [121 and type 1 plasminogen activator inhibitor
(PAl-i) [14, 151.
Because certain laboratory abnormalities were observed to occur
in the patients with chronic renal failure [6, 16—20], a prospective
study was designed to examine hemostasis-derived cardiovascular
risk factors, endothelium-derived plasma proteins and desmopressin-
induced variations of some endothelium-derived specific factors in
these patients and compare them to similar measurements in normal
subjects.
Methods
Patients
Records of 43 patients started on maintenance hemodialysis in
the Department of Nephrology of NImes Hospital were examined.
Patients having a past history of angina pectoris, myocardial
infarction, transient ischemic attack or complete stroke, acute or
symptomatic chronic peripheral arterial ischemia, diabetes, vas-
culitis or systemic lupus erythematosus were excluded. All remain-
ing patients who gave their informed consent to participate to this
study were included. All had normal electrocardiographic pat-
terns.
Twenty-two uremic patients (13 males and 9 females, median
age 59, range 18 to 77) entered the study. Renal failure had
resulted from polycystic disease in five and glomerulonephritis in
seventeen. All patients received the same treatment: 9 to 10.5
hours a week on hollow fiber' dialyzers (Beilco, Mirandola, Italy;
1.3 m2 area) with cuprophan membranes (8 /.L). The blood flow
was kept at 300 mi/mm. The dialysate, used single pass, had the
following composition (in mmol/liter): Na 138, K 1.5, Ca 1.75, Mg
0.75, Cl 107, HCO3 34. The diet was low in salt (no added salt)
with a mean protein intake > 1 g/kg body weight. Vascular
connections with the hemodialysis device had been done by way of
a previously performed arteriovenous fistula. The median dura-
tion of dialysis treatment was 46 months (range ito 183 months).
None of the patients had any evidence of illness other than
uremia. The pre-dialysis mean arterial pressure (MAP) was
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calculated [MAP = diastolic + (systolic — diastolic)!3] for each
patient and the month before the biological investigation (from
average value of all sessions of the month).
Patients with at least one vascular thrill (except for arterio-
venous fistula) or at least one non-pulsatile peripheral artery were
considered as positive for peripheral vascular disease (PVD).
Patients who had suffered from arteriovenous fistula thrombosis
were classified as "fistula thrombotic patients" (FTP). None of the
patients had suffered from deep vein thrombosis.
A control group of 22 healthy volunteers (aged 52, range 22 to
65, 13 men and 9 women) was recruited among the medical staff
and their friends at the same time as their matched uremic
patient.
Design of the study
DDAVP (desmopressin; MINIRINR, Ferring AB pharmaceu-
ticals, Malmo, Sweden) was given intravenously (0.3 gfkg body
wt). The total dDAVP dose was diluted in 100 ml saline solution,
and infused over a 30 minute period, between 9.00 and 11.00 a.m.
Uremic patients had been first dialyzed 48 hours before
dDAVP infusion. Desmopressin was infused using the venous
network of the forearm with no arteriovenous fistula.
A venous blood sample was taken from the antecubital vein of
the forearm planned for infusion five minutes before the begin-
ning of dDAVP administration. An arterial blood sample was
taken five minutes after the end of infusion through an arterio—
venous fistula puncture (uremic patients) or a radial artery
puncture (control patients; forearm opposite to dDAVP infu-
sion).
Collection of blood
All vessel punctures were done using a 19 gauge needle and no
tourniquet. For hemostasis related assays, blood was collected in
silicone tubes containing 1 volume per 10 of the "C.T.A.D."
anticoagulant-antiplatelet solution (3.8% trisodium citrate, theo-
phylline, adenosine, dipyridamol; Diatube' H, Diagnostica Stago,
Asnières, France) [21] after systematic rejection of the first 2 ml of
blood and were centrifuged for 20 minutes at 2,500 g, at room
temperature. Tubes for fibrinolysis related assays were immedi-
ately immersed in melting ice and centrifuged at 4°C. Plasma
samples were stored at —85°C until assayed.
Laboratory methods
Non-hemostasis related assays. Due to desmopressin-induced
plasma volume variations, post-dDAVP values were corrected by
using a factor F defined as [100 minus packed cell volume (PCV)
after infusion]/[100 minus PCV before infusion].
Serum albumin concentrations were measured by laser nephe-
lometry (BNA, Behringwerke AG, Marburg, Germany).
Hemostasis related assays. All clotting assays were performed on
ST888 analyzer (Diagnostica Stago). Chromogenic assays were
performed on ST888 or on a microplate reader (Titertek Twin-
reader, Flow Laboratories SA, Putaux, France). Enzyme linked
immunosorbent assays (ELISAs) were read using the TwinreaderR.
Clottable fibrinogen (Fg) was measured using Clauss' method
[22] (Fibri Prest', Diagnostica Stago).
Factor VII activity (FVII activity) was determined by a syn-
thetic chromogenic method according to Seligsohn, Osterud and
Rapaport [23] (Stachrom' VII, Diagnostica Stago).
Chromogenic assays were used for type I plasminogen activa-
tor inhibitor activity (PAl-i activity) [Spectrolyse° (pL) PM,
Biopool, Umea, Sweden] [24] and for antithrombin III activity
(AT III; Stachrom' ATIII, Diagnostica Stago) [25].
Factor VII related antigen (FVII Ag) and von Willebrand
factor related antigen (vWF Ag) were assayed by ELISAs (Asse-
rachromR VII and Asserachrom' vWF, Diagnostica Stago) [26,
27].
Type 1 plasminogen activator inhibitor-related antigen (PM-i
Ag) was quantified using a monoclonal ELISA (Tintelize PM-i,
Biopool AB) [28]. This assay has been previously shown to be
relatively insensitive to changes in complexation of PM-i with
single-chain tissue type plasminogen activator and with urokinase-
type plasminogen activator, and its low reactivity to latent PAl-i
renders this method relatively insensitive to contamination of
plasma with platelet release products [28].
Type 2 plasminogen activator inhibitor-related antigen (PAI-2
Ag) plasma concentrations were measured by a monoclonal
ELISA (Tintelize°° PAI-2, BiopoolAB) in which the coated
catching antibody is the one described by Astedt et al [29].
Tissue-type plasminogen activator related antigen (t-PA Ag)
was assayed by an ELISA (Tintelize°° t-PA, Biopool), which uses
the monoclonal antibody referred to as 1:3D3 in Stigbrand's
characterization work [30]: this antibody recognizes with a high
affinity a conformation dependent epitope on single-chain and
two-chains t-PA, and binds to t-PA!PAI-1 complexes.
Urokinase-type plasminogen activator (u-PA Ag) was mea-
sured with an ELISA reagent kit (Tintelize'TM u-PA, Biopool AB)
which uses a previously described catching monoclonal antibody
[3i]. This antibody binds to single-chain urokinase-type plasmin-
ogen activator (scu-PA) and to high molecular weight two-chain
urokinase type plasminogen activator (HMW/tcu-PA), but not to
low molecular weight/tcu-PA.
Soluble thrombomodulin (TM) plasma levels were quantified
by ELISA (Asserachrom' Thrombomodulin, Diagnostica Stago)
[32]. Thrombomodulin is a glycoprotein that is mainly present on
the cell surface membranes of endothelium. Its soluble plasma
fraction derives from the degradation of endothelial thrombo-
modulin by various proteases in the process of vascular endothe-
hal cell destruction [33].
All these assays were calibrated using reference plasmas and
purified standards given by the manufacturers. All assays were
performed in triplicate and we used the obtained median values.
For each test, within-assay variations (N = iO) and between-assay
variations (N = 10) were determined using 15 different plasmas
(5 low values, 5 normal values, 5 high values). In a given test, we
used the worse value of the obtained within-assay and between-
assay variations as the final coefficient of variation. Desmopressin
induced variations of values (that is, "delta" parameter: value
after infusion minus value before infusion) were calculated. In this
case, for a given biological test, only delta values greater or lower
than two final coefficient of variation values were considered as
individual significant variations. Other values were considered
nonsignificant and used as null values.
Statistical analysis
Results are given as median and range values.
Comparisons between groups of data were performed using
non-parametric tests: the Mann-Whitney rank sum U test (non-
paired data) and the Wilcoxon's signed-rank T test (paired data).
P > 0.05 was considered not significant. In order to limit the
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Table 1. Values of predialysis biological assays obtained in the control
group (C) and in the patient group (P)
Parameter Group
Median
value
Minimum
value
Maximum
value
P
Mann-Whitney
Albumin C 47.9 43.2 58.8
g/liter P 38.2 29.7 47.8 i0
Packed cell C 41.6 35.2 45.3
volume % P 25.6 21.0 33.2 1.4 10—8
Fibrinogen
g/liter
C
P
2.50
3.80
1.72
2.25
3.62
6.75 4 iO
F VII activity C 94 70 113
% P 116 103 133 1.6 10—6
FVIIAg C 96.0 71.5 116
% P 129 96 186 3106
PAl-i activity C 5.3 1.6 17.0
U/mi P 27.5 2.1 37.7 6 10—6
PAT-i Ag C 10.7 2.4 21.4
ng/mi P 13.8 2.8 46.5 2 102
vWF Ag C 100.5 64.5 156.0
% P 199.0 94.5 344.0 6 10_6
t-PA Ag
ng/ml
C
P
4.2
6.5
1.3
3.6
9.1
21.5 2 10
u-PA Ag C 0.29 0.19 0.53
ng/ml P 0.59 0.29 1.40 106
PAI-2 Ag C 2.4 1.0 4.2
ng/mi P 2.2 0.0 14.9 0.54 NS
AT III activity C 94.5 86.0 103.0
% P 83.5 65.0 118.0 10-2
Soluble TM C 29.5 16.5 51.0
ng/mi P 198.0 98.0 444.0 10_8
Abbreviations are: F VII activity, proconvertin activity; FVII Ag,
proconvertin related antigen; PAT-i activity, type 1 plasminogen activator
inhibitor activity; PAl-i Ag, type 1 plasminogen activator inhibitor-related
antigen; vWF Ag, von Willebrand factor-related antigen; t-PA Ag, tissue-
type plasminogen activator-related antigen; u-PA Ag, urokinase-type
plasminogen activator-related antigen; AT III activity, antithrombin III
activity; soluble TM, plasma soluble thronibomodulin-related antigen.
generation of Type II errors, only statistical comparisons which
type I error risk (false positive risk) had been calculated to be
below 0.05 and which type Ii error risk (false negative risk)
corresponding to a 5% type I error risk was also below 5% were
considered significant.
Limited correlations between data were performed using
Spearman's coefficient of rank correlation "r".
Results
The median mean arterial pressure value found in our patients
on regular hemodialysis was 100 mm Hg (range 76.8 mm Hg to
114.7 mm Hg). They had significantly lower packed cell volume
(PCV) and serum albumin concentrations than controls (Table 1).
On the other hand, uremic patients had higher plasma concen-
trations of the established cardiovascular risk factors: fibrinogeri,
FVII activity, FVII Ag, PAl-i activity and PAl-i Ag. The endo-
thelium-derived proteins t-PA Ag, u-PA Ag, vWF Ag and soluble
thrombomodulin (TM) were also higher in patients than in
controls. Uremic patients had generally decreased AT III activi-
ties, but three had higher AT III than the maximum value found
among members of the control group.
Desmopressin infusions performed in members of the control
group and in patients induced a significant decrease of albumin
concentrations (values are given in Table 2 and Fig. 1. Wilcoxon
paired t-test, P = 1.3 io and 9.8 i0, respectively). DDAVP
also induced an increase of t-PA Ag, vWF Ag and u-PA Ag
Table 2. Matrix of Spearman's rank correlations obtained between
some predialysis haemostasis related parameters in patients
Abbreviations are: PAT-i Ag, type 1 plasminogen activator inhibitor-
related antigen; vWF Ag, von Willebrand factor-related antigen; t-PA Ag,
tissue-type plasminogen activator-related antigen; TM, plasma soluble
thrombomodulin-related antigen.
(control group, P = 7.6 10 for the 3 dDAVP induced variations;
patients, respectively P = 1.3 iO, P = 7.6 10—6 and P = 1.0
10). Patients had dDAVP-induced lower releases of t-PA Ag
and vWF Ag than those evidenced in controls (Mann-Whitney U
test; Fig. 1). They also experienced a lower desmopressin induced
decrease of serum albumin values.
In patients, none of the predialysis hemostasis parameters
values were significantly correlated with the existence of a past
history of arteriovenous fistula thrombosis (AVF) or with the
presence of asymptomatic peripheral vascular disease (PVD).
Peripheral vascular disease was only significantly correlated to the
cumulative number of performed dialysis treatments (r' = 0.560,
P = 0.01). PM-i Ag, t-PA Ag, vWF Ag and TM values are
correlated in Table 3.
Studies undertaken in the control group between some of the
desmopressin induced variations of biological parameters (
parameters: albumin, t-PA Ag, u-PA Ag, z vWF Ag, z
PAl-i Ag) only showed a positive correlation between z t-PA Ag
and vWF Ag (r' = 0.647,P = 0.003) and a negative one between
albumin and PM-i Ag (r' =
—0,647, P = 0.003). In patients,
arteriovenous fistula thrombotic antecedents and asymptomatic
peripheral vascular disease clinical symptoms were not correlated
to these dDAVP induced variations. The number of performed
dialysis treatments was positively correlated to albumin (r'
0.695, P = 0.002) but negatively to PAl-i Ag (r' = —0.702, P =
0.001), t t-PA Ag (r' = —0.628, P = 0.004) and to i vWF Ag(r' =
—0.505,P = 0.021). There was a weak correlation between
t-PA Ag and iX vWF Ag, while t-PA Ag, i PAT-! and L PAl-i
Ag were altogether highly correlated (Table 3). Serum albumin
variations were negatively linked to PM-i Ag and t-PA Ag
variations.
Discussion
Since there is accumulating evidence that cardiovascular com-
plications represent the first cause of mortality in patients with
chronic renal failure, we decided to perform studies of the
so-called hemostasis-derived cardiovascular risk factors in pa-
tients who are on regular hemodialysis treatment. As endothelium
is thought to be involved in the atherogenetic process, we also
assayed basal plasma concentrations of some endothelium-de-
rived glycoproteins. We finally used desmopressin infusions as a
tool to study one of the endothelial cell properties: the release
capacity of intracellular t-PA and vWF.
The studied hemostasis-derived cardiovascular risk factors were
A A A A A
-
Albumin PAL-i Ag i-PA Ag vWF Ag u-PA Ag
A Albumin —0.964 —0.856 —0.255 0.197
P <0.0001 0.0001 0.243 0.367
A PAl-I Ag 0.875 0.365 —0.148
P 0.0001 0.095 0.498
S i-PA Ag 0.488 0.001
0.025 0.998
S vWF Ag —0.221
P 0.312
A u-PA Ag
P
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Fig. 1. Desmopressin induced variations of (A) albumin and urokinase-Lype
plasminogen activator-related antigen (u-PA Ag), and (B) tissue-type plas-
minogen activator antigen (t-PA Ag) and von Willebrand factor antigen (vWF
Ag) obtained in the control group (C) and in patients (P). Variations are
given using the delta parameter (value after dDAVP infusion minus value
before dDAVP infusion). Mann-Whitney's U test was used to perform
statistical comparisons.
fibrinogen, factor VII (antigen and coagulant activity) and type 1
plasminogen activator inhibitor (antigen and activity). All these
parameters were higher in patients than in controls. High values
Table 3. Matrix of Spearman's rank correlations obtained between
some desmopressin induced variations ( parameter) of hemostasis
related parameters in patients
Abbreviations are: PAl-i Ag, type 1 plasminogen activator inhibitor-
related antigen; vWF Ag, von Willebrand factor-related antigen; t-PA Ag,
tissue-type plasminogen activator-related antigen; u-PA Ag, urokinase-
type plasminogen activator-related antigen.
of these parameters are classically associated with a high risk of
arterial thrombotic disease [11—15], and hyperfibrinogenemia or
high proconvertin plasma concentrations have been consistently
found in uremia [16, 17]. Predialysis antithrombin III plasma
levels were lower in patients than in controls; this is concordant to
previously published data [17]. Three out of the 22 patients had
plasma ATIII concentrations higher than extreme values found in
controls, Prospective studies in the Northwick Park Heart Study
have led Meade et alto suggest that both low and high levels of
ATI1I may be associated with the risk of death from arterial
disease [34]. Low predialysis serum albumin concentrations were
also found in patients. Hemodilution due to water retention
together with prolonged reduction of protein intake should con-
tribute to hypoalbuminemia. However, Phillips, Shaper and
Whincup have previously shown a general highly significant
association between low serum albumin concentrations and mor-
tality from cardiovascular diseases [35]. Thus, in patients on
regular dialysis treatment, all studied plasma parameters where
basal concentrations are known to be associated to arterial
thrombotic events indicated a higher cardiovascular risk than in
controls. The underlying mechanisms deserve to be investigated.
Fibrinogen and PAl-i are acute phase proteins which rise in
response to several stimuli, including soluble cytokines like inter-
leukin-1 (IL-i), tumor necrosis factor (TNF) and interleukin 6
(IL-6) [36—38]. These cytokines suppress household genes, and
particularly the albumin gene [reviewed in 39]. Atherosclerosis is
a chronic inflammatory disorder. Due to the simultaneous pres-
ence of IL-i and TNF-cs in the plasma of long-term hemodialysis
patients, hemodialysis has been assimilated to a recurrent acute
phase inflammatory response [40]. This may at least partly
account for the observed fibrinogen, PAT-i and albumin levels.
High TNF-c concentrations have been recently demonstrated in
human atherosclerotic arterial walls and could be actively in-
volved in atherogenesis [41].
Patients also had higher predialysis plasma concentrations of
endothelial-derived glycoproteins than controls, namely tissue-
type plasminogen activator, von Willebrand factor, soluble throm-
bomodulin and urokinase-type plasminogen activator. The factor
VIII complex has been extensively investigated in uremia and
levels of vWF Ag are usually elevated [18, 19]. Von Willebrand
A
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factor is synthesized predominantly by vascular endothelial cells
and, to a lesser degree, by megakaryocytes [42, 43]. The admin-
istration of dDAVP to normal subjects has allowed the calculation
of a half-life of vWF Ag as 565 35 minutes (mean SCM) [44],
and vWF Ag kinetics after dDAVP infusions are not different in
uremic patients and in controls [8]. High plasma vWF Ag levels
could also be related to a hyperstimulation of vWF endothelial
secretion pathways. VWF is an acute phase reactant protein.
Thrombin, IL-i, gamma interferon, endotoxin, fibrin monomers,
and the surface assembly of the complement C5b-9 can rapidly
release vWF from cultured endothelial cells in a calcium depen-
dent manner in vitro [45]. High levels of vWF antigen have been
found in vasculitis of different origin [46] and in septicemia [47],
conditions with damage to the vascular endothelium, and also in
several diseases known to affect the vascular system such as
diabetes [48], active glomerulonephritis and peripheral artery
disease [49]. Brinkhous and coworkers have reported increased
plasma levels of vWF in dogs after experimentally-induced endo-
thelial damage [50]. These findings have led to the proposal that
raised plasma levels of vWF may indicate endothelial damage.
Theoretically, platelet activation could also have contributed to
the elevated plasma vWF Ag. Activation of platelets is known to
be the rule in patients on long-term hemodialysis [51], and platelet
activation has already been proposed to elevate plasma vWF Ag
[52]. However, in normal subjects, platelet origin vWF represents
only 10 to 25% of the plasma pool [53]. Platelet levels of our
patients were within normal values and there is no evidence that
a non-extreme platelet activation or lysis can really produce a
significantly elevated plasma vWF Ag.
A hyperfibrinolytic state is frequently found in uremia, which is
associated with increased plasmin generation [16, 17]. T-PA is the
main active plasminogen activator in euglobulin clot lysis and
fibrin plate assays. Like vWF, t-PA is mainly synthesized in
endothelial cells and may be released under the influence of
different stimuli: exercise, venous occlusion, vasopressin analogs,
thrombin itself [54, 55]. However, IL-i and TNF-a are known to
reduce t-PA synthesis by human umbilical vein endothelial cells in
vitro [56]. The in vivo half-life of t-PA is short: 3.1 minutes for
t-PA activity and 4.1 minutes for t-PA antigen. The liver removes
most of the freely circulating t-PA, t-PA/PAI complexes being
eliminated at a lower rate than free t-PA [57]. The rapid plasma
clearance of t-PA involves receptor-mediated endoyctosis, and
occurs by way of the heavy chain, most exclusively in the liver [58].
Our patients did not have the usual clinical and biological
indicators of hepatocyte insufficiency. The kidneys did not signif-
icantly alter the concentration of t-PA Ag and t-PA activity of the
blood [57] and high t-PA Ag plasma concentrations cannot be a
direct consequence of renal insufficiency itself. High basal plasma
t-PA Ag levels should rather be explained by a non-IL-i depen-
dent or by a TNF-a-dependent endothelial stimulation, by vascu-
lar endothelium damage, or perhaps by both mechanisms.
High predialysis soluble thrombomodulin levels were found in
the patients' plasma. Thrombomodulin is a glycoprotein with a
molecular weight of approximatively 105 kD that is present on the
cell surface membrane of endothelium [59]. The increase in the
plasma-free TM level is considered to be a marker of endothelial
injury [33]. In patients undergoing hemodialysis, a positive corre-
lation has previously been found between the TM predialysis
value and the duration of dialysis, and TM was proposed as a
marker of vascular disorders [20]. TM plasma levels are also
elevated in patients with acute renal failure and creatinine, and
TM levels are positively correlated [60]. Soluble TM is found in
human urine [61]. Plasma TM is probably physiologically filtrated
into urine through glomerular membrane, as the molecular weight
of soluble TM in plasma were found to be 28 to 105 kD [62].
However, due to the broad range of predialysis TM values
observed in our patients with chronic renal failure, part of the
high TM concentrations in patients is probably due to endothelial
injury.
Patients had higher predialysis u-PA Ag values than controls.
u-PA is synthesized by monocytes, epithelial cells and vascular
endothelial cells [63]. Data obtained from the pharmacokinetic
studies of purified single-chain u-PA establish a turnover in blood
with an initial tl/2 of about three minutes, and a hepatic clearance
[64]. IL-i and TNF-a are known to induce the production of
urokinase-type plasminogen activator by human endothelial cells
[65]. Moreover, Van Hinsbergh et al [66] have demonstrated in
vitro that human endothelial cells from aorta and other adult
arteries start secreting u-PA after one to four passages, parallel to
the occurrence of enlarged endothelial cells; the release of u-PA
antigen from human macrovascular endothelial cells is related to
the exhaustion to proliferate as a normal monolayer. This sug-
gested that the release of u-PA Ag by human macrovascular
endothelium could be an indicator of cell senescence.
Desmopressin induced vWF Ag and t-PA Ag releases were
lower in patients than in controls. These data are concordant with
those obtained by Winter et a! [6], who used a 15-minute venous
occlusion test to point to an impairment of endothelium capaci-
ties. Recent data in animal models have shown a close link
between the release of t-PA and that of vWF at the endothelial
level [67]. In this way, desmopressin-induced t-PA Ag and vWF
Ag releases were correlated in the control and the patient group,
but this correlation was weaker in dialyzed uremic patients. This
probably indicates a partial impairment of t-PA and vWF release
coupling at the cellular level. In patients desmopressin sometimes
induced an abnormal increase of albumin concentrations. Because
of similar dDAVP-induced packed cell volume variations in
patients and controls, this indicates albumin transfer from the
extravascular compartment to the intravascular compartment, and
probably denotes an impairment of the endothelial permeability
to macromolecules.
Thus, patients on prolonged maintenance hemodialysis with no
cardiovascular antecedent have biological cardiovascular risk
markers: high predialysis plasma levels of fibrinogen, proconvertin
and type 1 plasminogen activator inhibitor, low or high antithrom-
bin III levels, and low albumin concentrations. They also have
high plasma basal levels of endothelium-derived glycoproteins:
t-PA, vWF and u-PA. This should be related to high cytokine
plasma levels and should indicate a chronic endothelium activated
state. However, there is a sheaf of arguments for a chronic
endothelial damage: high soluble thrombomodulin concentra-
tions, reduced desmopressin induced vWF Ag and t-PA Ag
releases. IL-I and TNF-a are probably not in themselves injurious
to the endothelium, but cytokine-treated endothelial cells may be
more susceptible to injury, especially in activated leukocyte-
induced endothelial injury models, and may explain that in vivo
endothelial activation and endothelial injury often co-exist [68,
69]. Transient survivable disruptions of arterial endothelial cell
plasma membranes are far more commonplace than previously
suspected, and most of the mitotic endothelial cell are also
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wounded cells [70]. This may lead, in cases of associated uremic
levels of cytokines and toxins, to severe endothelial damage and
could be linked to the initiation of atherosclerosis. Moreover, the
accumulation of dialysis treatments seems to be associated with a
loss of desmopressin induced variations of vascular permeability
and of t-PAIvWF release. This could argue for a direct effect of
repeated dialysis runs on endothelial integrity, but the effects of
uremia and the effects of dialysis treatment per se are impossible
to separate.
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